Development of CMTM6 inhibitors: E!12710 Immune-Nova, Adlego Biomedical AB
| Reference number | |
| Coordinator | Adlego Biomedical AB |
| Funding from Vinnova | SEK 2 999 980 |
| Project duration | February 2019 - February 2023 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The goal was to verify that the test substance SC166 has an inhibitory effect on colon cancer, which we have not been able to verify.
Expected long term effects
The goal was to verify that the test substance SC166 has an inhibitory effect on colon cancer, which we have not been able to verify. Follow-up studies, which should test the compound in other cancer models, were not initiated since Scenic Biotech aimed at developing derivates of SC166 with better pharmacokinetic properties for better clinical use. The work with the derivates were not completed within the project period.
Approach and implementation
Under planning